NCT02343991进行中（未招募）不适用
A Study to Evaluate the Safety and Feasibility of Blood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound With Intravenous Ultrasound Contrast Agents in the Treatment of Brain Tumours With Doxorubicin
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- InSightec
- 入组人数
- 10
- 试验地点
- 2
- 主要终点
- Number of Device and Procedure related adverse events
研究概览
简要总结
The purpose of this study is to evaluate the safety of BBB disruption using transcranial MRI-guided focused ultrasound in conjunction with an intravenous ultrasound contrast agent to increase the accumulation of doxorubicin in brain tumours and the adjacent brain using the ExAblate Transcranial system (220 kHz). Data will be collected to establish the basic safety of this type of treatment as the basis for later studies to evaluate its clinical efficacy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men or women.
- •Age between 18 and 70 years, inclusive.
- •Able and willing to give informed consent.
- •Size of the targeted portion of the tumour (i.e. prescribed ROT) is less than 2.5 cm in diameter (16 cm3). The non-targeted tumour tissue may exceed the targeted volume.
- •Karnofsky rating 70-100
- •ASA score 1-
- •Able to communicate sensations during the ExAblate MRgFUS procedure.
- •Able to attend all study visits (i.e., life expectancy of at least 3 months).
- •At least 14 days passed since last brain surgery.
排除标准
- •The sonication pathway to the tumour involves:
- •i. More than 30% of the skull area traversed by the sonication pathway is covered by scars, scalp disorders (e.g., eczema), or atrophy of the scalp ii. Clips or other metallic implanted objects in the skull or the brain, except shunts
- •The subject presents with symptoms and signs of increased intracranial pressure (e.g., headache, nausea, vomiting, lethargy, and papilledema)
- •Cardiac disease or unstable hemodynamics including:
- •i. Documented myocardial infarction within six months of enrolment ii. Unstable angina on medication iii. Congestive heart failure iv. Left ventricular ejection fraction below the lower limit of normal v. History of a hemodynamically unstable cardiac arrythmia vi. Cardiac pacemaker
- •Severe hypertension (diastolic BP > 100 on medication)
- •Anti-coagulant therapy, or medications known to increase risk of hemorrhage, (e.g.:ASA, non-steroidal anti-inflammatory drugs (NSAIDs), statins)
- •History of a bleeding disorder, coagulopathy or with a history of spontaneous tumour hemorrhage
- •Abnormal level of platelets (< 100000), PT (>14) or PTT (>36), and INR > 1.3
- •Documented cerebral infarction within the past 12 months
- •TIA in the last 1 month
- •Cerebral or systemic vasculopathy
- •Insulin-dependent diabetes mellitus
- •Immunosuppression (corticosteroids to prevent/treat brain edema are permitted)
- •Known sensitivity to gadolinium-DTPA
- •Contraindications to MRI such as non-MRI-compatible implanted devices
- •Large subjects not fitting comfortably into the MRI scanner (generally >250 lbs)
- •Difficulty lying supine and still for up to 4 hours in the MRI unit or claustrophobia
- •Untreated, uncontrolled sleep apnea
- •Positive pregnancy test (for pre-menopausal women)
- •Known life-threatening systemic disease
- •Severely impaired renal function with estimated glomerular filtration rate <30 mL/min/1.73m2 and/or on dialysis
- •Right to left or bi-directional cardiac shunt
- •Previous full course of doxorubicin chemotherapy
- •Allergy to eggs or egg products
结局指标
主要结局
Number of Device and Procedure related adverse events
时间窗: At the time of ExAblate transcranial procedure
To evaluate the incidence and severity of adverse events (AEs) associated with the ExAblate transcranial treatment
次要结局
- Severity of Device and Procedure related adverse events(At the time of ExAblate transcranial procedure)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
不适用
Assessment of Initial Efficacy and Safety of High Intensity Focused Ultrasound 'ExAblate 4000 Type 2' for Blood Brain Barrier Disruption in Patients With Alzheimer's DiseaseAlzheimer DiseaseNCT04526262Yonsei University6
进行中（未招募）
1 期
Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPGBrain TumorNCT05615623InSightec10
进行中（未招募）
1 期
Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)Brain TumorNCT05630209InSightec10
已完成
不适用
Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects With GlioBlastoma Brain TumorsGlioblastomaLiquid BiopsyGliomaNCT05383872InSightec71
已完成
不适用
Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption for Treatment of GliomaGlioblastomaNCT03616860InSightec14